Inotiv, Inc. (NASDAQ:NOTV – Get Rating) – Equities research analysts at Jefferies Financial Group issued their Q1 2023 earnings per share estimates for Inotiv in a note issued to investors on Thursday, January 19th. Jefferies Financial Group analyst D. Windley forecasts that the company will earn ($0.44) per share for the quarter. Jefferies Financial Group has a “Hold” rating and a $8.00 price target on the stock. The consensus estimate for Inotiv’s current full-year earnings is $1.57 per share. Jefferies Financial Group also issued estimates for Inotiv’s Q2 2023 earnings at $0.04 EPS, Q3 2023 earnings at $0.29 EPS and Q4 2023 earnings at $0.46 EPS.
A number of other analysts have also recently commented on the stock. TheStreet cut shares of Inotiv from a “c-” rating to a “d+” rating in a research note on Wednesday, November 9th. Craig Hallum reduced their price target on Inotiv from $64.00 to $34.00 in a report on Wednesday, January 11th. Finally, Lake Street Capital upgraded Inotiv from a “hold” rating to a “buy” rating and set a $10.00 price objective on the stock in a research note on Wednesday, January 11th.
Inotiv Trading Up 5.4 %
Institutional Trading of Inotiv
Several hedge funds and other institutional investors have recently modified their holdings of NOTV. UBS Group AG acquired a new stake in Inotiv during the third quarter worth approximately $50,000. Quantbot Technologies LP boosted its stake in Inotiv by 30.8% in the 2nd quarter. Quantbot Technologies LP now owns 7,120 shares of the company’s stock valued at $68,000 after purchasing an additional 1,678 shares during the period. Amalgamated Bank acquired a new position in Inotiv in the 1st quarter valued at $78,000. JPMorgan Chase & Co. increased its position in Inotiv by 13.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 9,420 shares of the company’s stock worth $90,000 after buying an additional 1,136 shares during the period. Finally, Next Capital Management LLC acquired a new stake in shares of Inotiv during the fourth quarter worth $99,000. Institutional investors own 52.04% of the company’s stock.
Inotiv Company Profile
Inotiv, Inc operates as a pharmaceutical development company, which engages in the provision of drug discovery, development services, and analytical instruments. The firm operates through the following business segments: Research Services and Research Products. The Research Services segment provides screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance, and quality control testing.
- Get a free copy of the StockNews.com research report on Inotiv (NOTV)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for Inotiv Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inotiv and related companies with MarketBeat.com's FREE daily email newsletter.